Gilotrif & Malignant neoplasm progression

17.2%

of users reported Malignant neoplasm progression

82.9%

also reported Severe reaction

52.2%

are women

Severe reaction

82.9%

Death

12.7%

Hospitalization

3.1%

Life-threatening condition

1.3%

Disability

0.1%

Gilotrif: general information

30 - 39 years

2.1%

40 - 49 years

5.6%

50 - 59 years

17.3%

60 - 69 years

33.1%

70 - 79 years

30.1%

80 - 89 years

11.3%

90 - 99 years

0.5%